US FDA approves Arrowhead's genetic disorder drug
18/11/2025 16:19
Nov 18 (Reuters) - The U.S. Food and Drug Administration approved Arrowhead Pharmaceuticals' ARWR.O drug for a type of genetic disorder that causes extremely high levels of fat in the bloodstream, the health regulator's website showed on Tuesday. (Reporting by Padmanabhan Ananthan and Christy Santhosh in Bengaluru; Editing by Tasim Zahid) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors